SECAUCUS, N.J., June 23, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2025 financial ...

Quest Diagnostics DGX is well-poised to grow in the coming quarters, supported by its value-creating, strategic acquisitions. The company’s Advanced Diagnostics offerings deliver and scale innovative ...

Represents estimated pre-tax charges of $37 million primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business.

Represents estimated pre-tax charges of $41 million primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business.

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Quest Diagnostics (DGX) been one of those stocks this year?

Quest Diagnostics (NYSE:DGX) has had a rough month with its share price down 5.3%. But if you pay close attention, ...

Quest Diagnostics' fair value estimate remains steady at $197.25 per share, with only a slight uptick in the discount rate. This reflects minimal change in the firm's valuation assessment. While the ...